Trial reportJournal of acquired immune deficiency syndromes (1999)2022
Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV.
Trial report in Journal of acquired immune deficiency syndromes (1999), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02344290. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Synergy of SARS-CoV-2 and HIV-1 Infections in the Human Brain.Pathogens (Basel, Switzerland) · 2026Review
- SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa.AIDS (London, England) · 2025Article
- Difference of SARS-CoV-2 infection and influence factors between people with and without HIV infection.BMC public health · 2025Article
- Are older adults living with HIV more susceptible to omicron infection compared to their HIV-negative peers in China: a cross-sectional study.Frontiers in public health · 2025Article
- Deciphering long-term immune effects of HIV-1/SARS-CoV-2 co-infection: a longitudinal study.Medical microbiology and immunology · 2024Article
- People living with HIV with the Omicron variant infection have milder COVID-19 symptoms: results from a cross-sectional study.AIDS research and therapy · 2024Article
- Effect of host factors and COVID-19 infection on the humoral immune repertoire in treated HIV.JCI insight · 2023 · on this mapArticle
- Article
- Incidence and severity prediction score of COVID-19 in people living with HIV (SCOVHIV): experience from the first and second waves of the pandemic in Indonesia.AIDS research and therapy · 2022Article
- Non-neutralizing antibodies: Deleterious or propitious during SARS-CoV-2 infection?International immunopharmacology · 2022Review
- Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 15 institutions in 2 countries.
Funding
Abstract
backgroundLimited data are available regarding asymptomatic COVID-19 among people with HIV (PWH). Data on a representative subset of PWH enrolled in Randomized Trial to Prevent Vascular Events in HIV, a global clinical trial, are presented here.
methodsRandomized Trial to Prevent Vascular Events in HIV is an atherosclerotic cardiovascular disease prevention trial among 7770 PWH on antiretroviral therapy. Beginning April 2020, targeted data on coronavirus disease 2019 (COVID-19) diagnosis and symptoms were collected during routine trial visits. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was defined as either COVID-19 clinical diagnosis or presence of SARS-CoV-2 Immunoglobulin G (IgG) or Immunoglobulin A (IgA) receptor binding domain protein (antispike) antibodies in the absence of prior COVID-19 vaccine.
resultsThe group (N = 2464) had a median age 53 years, 35% female sex, 47% Black or African American race, median CD4 count 649 c/mm 3 , and 97% with HIV VL <400 cp/m. SARS-CoV-2 infection occurred in 318 persons (13%): 58 with clinical diagnosis and 260 with detectable antibodies. Of these PWH, 304 completed symptom questionnaires: 121 (40%) reported symptoms, but 183 (60%) were asymptomatic. PWH with asymptomatic SARS-CoV-2 infection were more likely to be from low-income or middle-income regions, of Black or African American race, older in age, and with higher atherosclerotic cardiovascular disease risk score. Symptomatic COVID was more common with obesity, metabolic syndrome, and low HDL levels. CD4 counts and HIV viral suppression rates were similar among PWH with symptomatic vs. asymptomatic COVID.
conclusionsAsymptomatic SARS-CoV-2 infection is common among antiretroviral therapy-treated PWH globally. We determined that 60% of infections in PWH were asymptomatic. HIV clinicians must remain vigilant about COVID-19 testing among PWH to identify asymptomatic cases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.